Details for New Drug Application (NDA): 084853
✉ Email this page to a colleague
NDA 084853 describes CHLOROTHIAZIDE W/ RESERPINE, which is a drug marketed by Watson Labs and is included in two NDAs. Additional details are available on the CHLOROTHIAZIDE W/ RESERPINE profile page.
The generic ingredient in CHLOROTHIAZIDE W/ RESERPINE is chlorothiazide; reserpine. There are forty-two drug master file entries for this compound. Additional details are available on the chlorothiazide; reserpine profile page.
The generic ingredient in CHLOROTHIAZIDE W/ RESERPINE is chlorothiazide; reserpine. There are forty-two drug master file entries for this compound. Additional details are available on the chlorothiazide; reserpine profile page.
Summary for 084853
| Tradename: | CHLOROTHIAZIDE W/ RESERPINE |
| Applicant: | Watson Labs |
| Ingredient: | chlorothiazide; reserpine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG;0.125MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
